NCT05340647 NorMIGS - a Study of Micro-invasive Glaucoma Surgery
| NCT ID | NCT05340647 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Oslo University Hospital |
| Condition | Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2022-04-22 |
| Primary Completion | 2023-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2022-04-22 with a primary completion date of 2023-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
NorMIGS is a non-randomized clinical study of intraocular pressure lowering effect and complications after Preserflo microshunt implantation versus other types of glaucoma surgery. The study is conducted in the Department of Ophthalmology, Oslo University Hospital, Norway.
Eligibility Criteria
Inclusion Criteria: * Patients must be 18 years or older at the time of signing the informed consent form. There is no upper age limit. * Scheduled for implantation of Preserflo microshunt, trabeculectomy or other types of MIGS * Ability to cooperate fairly well during the examinations * Willing to participate in the study and capable of providing informed consent Exclusion Criteria: \- High intraocular pressure due to increased episcleral venous pressure, hemorrhagic glaucoma, traumatic glaucoma or uveitis glaucoma
Contact & Investigator
Olav Kristianslund, MD PhD
PRINCIPAL INVESTIGATOR
Department of Ophthalmology, Oslo University Hospital
Frequently Asked Questions
Who can join the NCT05340647 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05340647 currently recruiting?
Yes, NCT05340647 is actively recruiting participants. Contact the research team at olakri@ous-hf.no for enrollment information.
Where is the NCT05340647 trial being conducted?
This trial is being conducted at Oslo, Norway.
Who is sponsoring the NCT05340647 clinical trial?
NCT05340647 is sponsored by Oslo University Hospital. The principal investigator is Olav Kristianslund, MD PhD at Department of Ophthalmology, Oslo University Hospital. The trial plans to enroll 100 participants.